Protein Arginine Methyltransferase-5 Inhibition Induces Growth Arrest and Death in Triple-Negative Breast Cancer Cells
Future Pharmacology · 24.07.2026 · 6 (3) · 40
DOI: 10.3390/futurepharmacol6030040 ↗Kurz gefasst
Fachartikel in der Zeitschrift Future Pharmacology, online erschienen am 24.07.2026. Verfasst von Majdi Al-Alawneh und 4 weiteren Autor:innen. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
PRMT5, or protein arginine methyltransferase 5, is recognized as an epigenetic regulator that suppresses gene transcription through symmetric dimethylation of histone arginine residues, including histone H4 arginine 3 (H4R3me2s) and histone H3 arginine 8 (H3R8me2s), modifications associated with chromatin condensation and transcriptional repression. PRMT5-mediated methylation has been associated with recruitment of polycomb repressive complex 2 (PRC2) and enhancer of zeste homolog 2 (EZH2)-mediated H3K27me3 deposition, contributing to stable repression of tumor suppressor genes and apoptosis-related effectors in breast cancer.
Methods
The molecular and functional impacts of PRMT5 inhibition were studied in TNBC cell lines with a pharmacological inhibitor (CMP5). Cellular responses were evaluated using a viability assay, qPCR, Western blotting, Annexin V/PI staining, and transwell migration/proliferation assays.
Results
PRMT5 inhibition substantially reduced TNBC viability in a time- and dose-dependent manner. EZH2 was downregulated, whereas the tumor suppressor retinoblastoma-like protein 2 (RBL2) was induced, concomitant with low expression of Cyclin D1. These changes were accompanied by upregulation of pro-apoptotic effectors (Caspase-3, Caspase-10, death-associated protein 1 (DAP1), and BCL2-associated x protein (BAX) and repression of the pro-survival B-cell lymphoma 2 (BCL2), consistent with apoptosis-associated molecular responses. Functionally, CMP5 treatment was associated with reduced migratory behavior in TNBC cells under the experimental conditions tested.
Conclusions
These findings suggest that PRMT5 inhibition by CMP5 is associated with reduced TNBC cell viability, impaired migration, increased expression of apoptosis-associated regulators and enhanced apoptotic cell death as measured by Annexin V/PI analysis in vitro. Further mechanistic and in vivo studies are required to clarify the therapeutic relevance of PRMT5 inhibition in TNBC.
Zitieren
APA
Al-Alawneh, M., Ahmad, F., Abdallah, A. M., Jaoua, S., & Sif, S. (2026). Protein Arginine Methyltransferase-5 Inhibition Induces Growth Arrest and Death in Triple-Negative Breast Cancer Cells. Future Pharmacology, 6(3), 40. https://doi.org/10.3390/futurepharmacol6030040
Vancouver
Al-Alawneh M, Ahmad F, Abdallah AM, Jaoua S, Sif S. Protein Arginine Methyltransferase-5 Inhibition Induces Growth Arrest and Death in Triple-Negative Breast Cancer Cells. Future Pharmacology. 2026;6(3):40. doi:10.3390/futurepharmacol6030040
BibTeX
@article{AlAlawneh2026,
author = {Al-Alawneh, Majdi and Ahmad, Fareed and Abdallah, Abdallah Musa and Jaoua, Samir and Sif, Saïd},
title = {Protein Arginine Methyltransferase-5 Inhibition Induces Growth Arrest and Death in Triple-Negative Breast Cancer Cells},
journal = {Future Pharmacology},
year = {2026},
volume = {6},
number = {3},
pages = {40},
doi = {10.3390/futurepharmacol6030040}
}
EUVIMED